Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.
Vijay Maruti PatilVanita NoronhaNandini Sharrel MenonAjay SinghSarbani Ghosh LaskarAshwini BudrukkarAtanu BhattacharjeeMonali SwainVijayalakshmi MathrudevKavita NawaleArun BalajiZoya PeelayMitali AloneShruti PathakAbhishek MahajanSuman KumarNilendu PurandareArchi AgarwalAmeya D PuranikShantanu PendseMonica Reddy YallalaHarsh SahuVenkatesh KapuSayak DeyJatin ChoudharyMadala Ravi KrishnaAlok ShettyNaveen KaruvandanRahul RavindRahul RaiKunal JobanputraPankaj ChaturvediPrathamesh S PaiDevendra ChaukarSudhir Vasudevan NairShivakumar ThiagarajanKumar PrabhashPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The addition of docetaxel to radiation improved DFS and OS in cisplatin-ineligible patients with LAHNSCC.[Media: see text].